Ticagrelor

BreastfeedingPediatric

FDA APPROVAL DATE: 07/20/2011

CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Atazanavir, Carbamazepine, Clarithromycin, Dexamethasone, Digoxin, Efavirenz, Indinavir, Itraconazole, Ketoconazole, Lovastatin, Nefazodone, Nelfinavir, Phenobarbital, Phenytoin, Rifampin, Ritonavir, Saquinavir, Simvastatin, Telithromycin, Venetoclax, Voriconazole

PREGNANCY CATEGORY: C

Maintenance doses of aspirin above 100 mg reduce the effectiveness of ticagrelor and should be avoided.

Contra-indicated in patients with a history of intracranial hemorrhage, or active pathological bleeding, and in patients with severe hepatic impairment.

BLEEDING RISK

See full prescribing information for complete boxed warning.

Our database has 39 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Page last updated 05/21/2020

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top